Forefront Analytics’s Fusion Pharmaceuticals FUSN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-16,715
Closed -$161K – 70
2023
Q4
$161K Sell
16,715
-16,970
-50% -$82.5K 0.08% 56
2023
Q3
$87.6K Buy
33,685
+13,610
+68% +$43.6K 0.05% 55
2023
Q2
$93.8K Buy
+20,075
New +$86.8K 0.05% 58

Other funds holding FUSN

Forefront Analytics's FUSN Position: Q1 2024 in Review

Forefront Analytics sold out of Fusion Pharmaceuticals (FUSN) in Q1 2024, closing a stake of 16,715 shares — an estimated $161K sold.

Forefront Analytics first reported a position in FUSN in Q2 2023 and held it in 3 quarters. The position peaked at $161K in Q4 2023. 114 funds tracked by Wall St. Rank hold FUSN as of Q1 2024.

  • Forefront Analytics reported no remaining Fusion Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Forefront Analytics sold 16,715 Fusion Pharmaceuticals shares in Q1 2024, an estimated $161K.
  • Forefront Analytics first reported a position in Fusion Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Forefront Analytics's Fusion Pharmaceuticals position peaked at $161K in Q4 2023.
  • 114 funds tracked by Wall St. Rank held Fusion Pharmaceuticals as of Q1 2024.

Based on Forefront Analytics's 13F filing for Q1 2024, filed 15 May 2024.